Clinical Trial Update: Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a single-dose GnRH agonist given in the luteal phase during GnRH antagonist-stimulated ICSI-ET cycles; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infertility

Drugs mentioned

• GnRH agonist (gonadotropin-releasing hormone agonist)

Snippet

Sponsor: V.K.V. American Hospital, Istanbul | Conditions: Infertility | Phase 3 | Status: TERMINATED